2 terminated, 2 withdrawn, 1 completed. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 2, Withdrawn 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow AMG 337: new trials by email Literature Review of AMG 337 trials Research Report on AMG 337
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma AMG 337 - Clear Cell Sarcoma | Phase 2 | Terminated | NantPharma, LLC | 8 | 2018-08-29 | 2024-05-24 |
| QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors AMG 337 - Solid Tumor | Phase 2 | Withdrawn | NantPharma, LLC | 2018-05-02 | 2019-08-28 | |
| C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer c-Met inhibitor AMG 337, placebo, oxaliplatin - Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | Phase 1 / Phase 2 | Withdrawn | Eastern Cooperative Oncology Group | 2015-03-06 | 2023-05-25 | |
| A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects AMG 337 - Stomach Neoplasms | Phase 1 / Phase 2 | Completed | Amgen | 11 | 2014-04-15 | 2021-12-28 |
| Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors AMG 337 - Stomach Neoplasms | Phase 2 | Terminated | Amgen | 60 | 2014-02-01 | 2017-07-02 |
Stomach Neoplasms (3) · Adenocarcinoma Of Esophagus (2) · Esophageal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Sarcoma, Clear Cell (1)
Amgen (2) · NantPharma, LLC (2) · Eastern Cooperative Oncology Group (1)
United States (4) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Japan (1) · Peru (1) · Poland (1)
Lakshmi Rajdev (1)
U10CA180820 (1)